Thirty two patients with active Crohn's disease were included in a controlled randomised trial to determine the efficacy and safety of polymeric enteral nutrition compared with steroids, to achieve and maintain clinical remission. The polymeric diet was administered through a fine bore nasogastric tube by continuous, pump assisted infusion (2800 (SEM 120) kcal/day). The steroid group received 1 mg/kg/day ofprednisone. Both treatments were effective in inducing clinical remission: 15 of the 17 patients given steroids and 12 ofthe 15 patients assigned to the polymeric diet went into clinical remission (defined by a Van Hees index <120) within four weeks of treatment. The percentage reduction of the Van Hees index was 34*8 (4.9)% for steroids and 32 3 (5)% for enteral nutrition (mean difference 2-5%; 95% CI -11-8% to +16-8%). Mean time elapsed to achieve remission was similar in both groups (2.0 (1) v 2-4 (1.2) weeks). Tolerance of the enteral diet was excellent. Four patients in the steroid group had mild complications attributable to this treatment. Ten patients (66.6%) in the steroid group and five (41.6%) in the enteral nutrition group relapsed within a year of discharge, but no differences were found in the cumulative probability of relapse during the follow up period. These results suggest that polymeric enteral nutrition is as safe and effective as steroids in inducing short term remission in active Crohn's disease.
ance of the enteral diet was excellent. Four patients in the steroid group had mild complications attributable to this treatment. Ten patients (66.6%) in the steroid group and five (41.6%) in the enteral nutrition group relapsed within a year of discharge, but no differences were found in the cumulative probability of relapse during the follow up period. These results suggest that polymeric enteral nutrition is as safe and effective as steroids in inducing short term remission in active Crohn's disease. (Gut 1993; 34: Elemental (aminoacid based) diets were initially introduced as primary treatment of active Crohn's disease because of their hypoallergenicity, because it was considered that whole protein may act as a dietary antigen and increase the immune stimuli to the gut.' Another argument for these diets was their possible role in favouring bowel rest. Six prospective randomised trials have evaluated the efficacy of elemental diets in Crohn's disease. In four of them, the elemental diet was as effective as steroid treatment in achieving short term remission. '-4 In one trial, elemental feeding was as effective as bowel rest plus total parenteral nutrition,5 but these results could not be reproduced in patients with colonic Crohn's disease. 8 Recent studies suggest that the effectiveness of elemental formulas is sustained by factors other than the so called bowel rest. 78 Also, polymeric (whole protein based) diets, when used as adjuncts to steroids, are well tolerated in active Crohn's disease. 9 Elemental diets have the inconvenience, however, of being unpalatable, hyperosmolar, and expensive. Therefore, other types of formula diets without such drawbacks have been assessed. In one study, hydrolysed (peptide based) diets were no better than steroid plus sulfasalazine treatment.'0 In another trial this type of diet was as effective as an elemental diet in inducing remission in active Crohn's disease." Four prospective randomised trials have investigated the role of polymeric formulas in Crohn's disease. In three of them, this diet was as effective as an elemental diet in achieving remission.'2 14 By contrast, opposite results were obtained in a recent study, with a very poor response to the polymeric diet.'5 Thus the question of which type of enteral formula diet is better in the treatment of Crohn's disease remains open, and a study comparing polymeric diets with steroid treatment has, to our knowledge, never been performed.
The aim of the present study was to evaluate the efficacy and safety of polymeric enteral nutrition, as compared with steroid treatment, in achieving and maintainimg clinical remission in patients with active Crohn's disease.
Patients and methods
From November 1988 until November 1991, all adult patients admitted because of clinically symptomatic Crohn's disease were prospectively evaluated. The diagnosis ofthe disease was based on previously reported clinical, morphological, and histopathological data.'6 Patients were considered for the trial on the basis of: (1) symptoms consistent with activity of the disease (abdominal pain, diarrhoea, weight loss, anorexia, fever); (2) two or more abnormal laboratory indices indicative of active disease (erythrocyte sedimentation rate (ESR). >30 mm/h, haemoglobin concentration (Hb) <12 g/dl for men and < 11 5 g/dl for women, C-reactive protein (CRP) >3 mg/l, platelet count >350000 cells/mm3); and (3) Van Hees activity index (VHAI)'7 greater than 120.
Patients were excluded from the study if they were already taking steroids, had evidence of intestinal perforation, significant intestinal obstruction, toxic megacolon, massive gastrointestinal haemorrhage, or mid-jejunal fistulas that precluded the use of enteral nutrition.
Forty four patients with Crohn's disease were examined for eligibility during the trial period. Twelve were excluded because of VHAI <120 (five patients), steroid treatment (four patients), refusal to participate in the study (two patients), and mental retardation (one patient). Thus Table I gives the composition of the polymeric formula diet. Polymeric enteral nutrition (PEN) was administered through a fine bore Silk type nasogastric tube (Corpak, Chicago, IL) by continuous, pump assisted infusion over 20-22 hours/day. No oral food or fluids were allowed during the trial. Daily total caloric requirements were calculated from Long's equation modified for ideal body weight.'8 A starter regimen was used, with infusion of 60% of the calculated total caloric requirements on the first day; this was progressively increased to 100% by the third day.
Patients randomised for steroid treatment received oral prednisone (1 mg/kg/day). If improvement was achieved, prednisone was gradually reduced by 10 mg weekly decrements down to 30 mg. Afterwards, prednisone was reduced in steps of 5 mg/week until completely withdrawn. While in hospital, patients taking steroids were encouraged to eat the whole hospital lactose free diet (mean daily caloric intake 2200 (230) kcal/day).
In both groups, treatment with sulfasalazine, azathioprine, cyclosporine A, or parenteral nutrition was not allowed. Two After remission was achieved, a western type lactose free oral diet was reintroduced in the PEN group within a period no longer than two days. In both groups, treatment with oral 5-ASA (500 mg mesalazine thrice daily) was started before discharge and maintained during follow up. Patients treated with steroids continued the decreasing steroid regime on an ambulatory basis and also had a western type lactose free oral diet. Milk derivatives were slowly reintroduced after one month of follow up in both groups.
Follow up included monthly visits during the first three months, and every three months afterwards. Relapse was defined as: (1) Cumulative probability ofrelapse duringfollow up in both groups (log rank test, p=0-21). Both groups were taking mesalazine (I 5 glday).
PEN group, there were three treatment failures. One of these patients improved when steroids were administered. The remaining two patients did not achieve remission after four weeks of treatment. They also failed to respond to steroids and were treated surgically. No preferential disease location was noted in treatment failures. Protein-energy nutritional status was maintained in both groups during the trial period. Nutritional support induced a significant increase in TSF, whereas normal hospital diet plus steroids did not. Similar significant increases in serum albumin concentration were found in both groups (Table V) .
Tolerance of the diet in the PEN group was excellent. One patient complained of heartburn and required the administration of H2 antagonists to relieve it. It is remarkable that no patient had diarrhoea attributable to diet intolerance, and the number of bowel movements decreased significantly in the PEN group (Table IV) . Four of the 17 (23-5%) patients in the steroid group had complications attributable to the treatment (two moon faces, one acne, and one hypokalaemia), but no difference in treatment related complication rate was found between groups (p=021). Fifteen patients relapsed during the follow up, 10 from the steroid group (66-6%) and five from the PEN group (41 6%). No differences were found in the cumulative relapse probability during follow up (p=0.21) (figure). Follow up in non-relapsing patients ranged from two to 41-7 months (median 9 Stool Changes in the VHAI were used as an end point in this study. This index, as it largely depends on laboratory measurements, is more objective than other indices including overall clinical assessment, such as the Crohn's disease activity index (CDAI).22-24 Also, the increase in the number of liquid or soft stools, an important item of CDAI, may be caused either because of worsening of the intestinal disease or as a side effect of enteral nutrition. This may induce misjudgment. Moreover, the use of the reduction of the VHAI instead of CDAI as the end point to calculate the sample size allowed us to study a smaller sample of patients than in previous work,10 for the same a and errors. This is due to the smaller variability of VHAI compared with CDAI. [22] [23] [24] In a unique trial comparing a non-elemental tube fed diet with steroids, Lochs et al suggested that a peptide based diet was less effective than a combination of methylprednisolone and sulfasalazine in treating active Crohn's disease.'0 The different results obtained with the polymeric diet used in our study are unlikely to be a consequence of the different protein composition. Peptides, less antigenic substrates than whole protein, are effective in inducing remission in Crohn's disease." Thus differences should be attributed to other factors. As previously mentioned , the use of CDAI as the criteria to assess clinical efficacy in the study of One fact seldom taken into account when comparing diets in the treatment of Crohn's disease is the possible differences in their fat Crohn's disease,"5 indicates that all of them had very low fat content (0-6 to 1-3% of total calories). When intermediate or high fat diets are used,'2-'5 the favourable or unfavourable clinical outcome might depend on the type of predominant fatty acids. In the present study, the polymeric diet used had both high fat (33% ofthe total calories) and high monounsaturated fatty acid (oleic acid) content. By contrast, the polymeric diet used in the study of Giaffer et al was high fat (36% of total calories) but also high in linoleic acid. This fatty acid is the precursor of arachidonic acid, which, in turn is the substrate for eicosanoid (LTB4, TxA2, PGE2) synthesis. Thus quantitative or qualitative differences in the lipid composition of the administered fat, saturated or monounsaturated v polyunsaturated oils, may modify the synthesis of eicosanoids and impair some immunomodulatory mechanisms that may influence the outcome when treating active Crohn's disease. Studies taking into account the lipid composition of the diets may help to further define the mechanism for the primary effect of enteral diets in active Crohn's disease.
In our present study, differences in relapse during follow up between both groups were not found, but relapse rate tended to be lower in the PEN group. This suggests that the remissions achieved with PEN were real, whatever the mechanism. This trend has to be confirmed with more patients and a longer follow up.
In conclusion, the results of our present study suggest that polymeric diets are a safe and effective treatment for active Crohn's disease. They are a well tolerated and a cheaper alternative to elemental diets, which merit serious consideration as treatment of active Crohn's disease, specially in malnourished patients or when steroid treatment is contraindicated. Further studies in a larger series are needed to ascertain which subgroups of patients with Crohn's disease are more prone to respond to diet treatment and to maintain longterm remission. 
